Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy

Authors

Aaron D. Schenone, Washington University School of Medicine in St. Louis
Jingqin Luo, Washington University School of Medicine in St. Louis
Luke Montgomery, Washington University School of Medicine in St. Louis
Daniel Morgensztern, Washington University School of Medicine in St. Louis
Douglas R. Adkins, Washington University School of Medicine in St. Louis
Brian A. Van Tine, Washington University School of Medicine in St. Louis

Journal

Cancer Medicine

Publication Date

2014

Volume

3

Issue

3

Inclusive Pages

603-612

Document Type

Open Access Publication

DOI

10.1002/cam4.209

Rights and Permissions

Aaron D. Schenone, et al. Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. Cancer Medicine 2014; 3(3): 603–612. DOI: 10.1002/cam4.209 Copyright 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Schenone, Aaron D.; Luo, Jingqin; Montgomery, Luke; Morgensztern, Daniel; Adkins, Douglas R.; and Van Tine, Brian A., "Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy." Cancer Medicine. 3, 3. 603-612. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/3770